TY - JOUR
T1 - Gynecological malignancies in elderly patients
T2 - Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study
AU - Ceccaroni, Marcello
AU - D'Agostino, Giuseppe
AU - Ferrandina, Gabriella
AU - Gadducci, Angiolo
AU - Di Vagno, Giovanni
AU - Pignata, Sandro
AU - Poerio, Antonella
AU - Salerno, Maria Giovanna
AU - Fanucchi, Antonio
AU - Lapresa, Maria Teresa
AU - Tambaro, Rosa
AU - Scambia, Giovanni
PY - 2002
Y1 - 2002
N2 - Objective. One hundred and forty-eight consecutive gynecological oncological patients aged ≥70 were administered chemotherapy during the years 1990-2000. Methods. Median age was 73 years (range 70-84). Fifty-five (37.2%) women were over 75 years old. One or more comorbid conditions were present in 118 (79.7%) patients. Standard schedules were administered to 97.3% of cases, with a total number of 1046 cycles of therapy administered (median, 6; range, 1-35, per patient). Results. Of a total of 233 chemotherapy regimens globally administered, G3-G4 hematological toxicity was documented in 38.2% of cases. Only 10 (6.8%) of the 148 patients discontinued treatment because of G3-G4 hematological toxicity. No severe nonhematological toxicity was observed. Two dose reductions and three treatment delays, but no discontinuation of treatment, were required during second-line regimens. Treatment delay >7 days was required in 16.9% of cases. Conclusions. Chronological age did not adversely influence the ability to receive aggressive treatment.
AB - Objective. One hundred and forty-eight consecutive gynecological oncological patients aged ≥70 were administered chemotherapy during the years 1990-2000. Methods. Median age was 73 years (range 70-84). Fifty-five (37.2%) women were over 75 years old. One or more comorbid conditions were present in 118 (79.7%) patients. Standard schedules were administered to 97.3% of cases, with a total number of 1046 cycles of therapy administered (median, 6; range, 1-35, per patient). Results. Of a total of 233 chemotherapy regimens globally administered, G3-G4 hematological toxicity was documented in 38.2% of cases. Only 10 (6.8%) of the 148 patients discontinued treatment because of G3-G4 hematological toxicity. No severe nonhematological toxicity was observed. Two dose reductions and three treatment delays, but no discontinuation of treatment, were required during second-line regimens. Treatment delay >7 days was required in 16.9% of cases. Conclusions. Chronological age did not adversely influence the ability to receive aggressive treatment.
KW - Age
KW - Chemotherapy
KW - Comorbidity
KW - Discontinuation
KW - Dose reduction
KW - Elderly
KW - Oncological
KW - Performance status
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=0036083557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036083557&partnerID=8YFLogxK
U2 - 10.1006/gyno.2002.6631
DO - 10.1006/gyno.2002.6631
M3 - Article
C2 - 12051872
AN - SCOPUS:0036083557
VL - 85
SP - 445
EP - 450
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -